Janet Brown on the phase 2/3 STAR trial

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Read the full article:

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR) (thelancet.com/journals/lanonc/article/PIIS1470…)00793-8/fulltext)

Tell us what you thought about this episode (buzzsprout.com/1391338/fan_mail/new)

Continue this conversation on social!

Follow us today at...

thelancet.bsky.social

instagram.com/thelancetgroup

facebook.com/thelancetmedicaljournal

linkedIn.com/company/the-lancet (linkedin.com/company/the-lancet)

youtube.com/thelancettv